WHAT’S NEW

Science Translational medicine Cover

Stroma Biosciences co-founders have been accepted as the cover story in Science Translational Medicine for their work on the tumour microenvironment. The research found that treating the normal cells near to the cancer cells with small molecule inhibitors significantly improved the effects of a broad range of chemotherapies
https://www.science.org/doi/10.1126/scitranslmed.aax9340

LATEST NEWS

Stroma Biosciences has made the #21toWatch Companies Longlist

Stroma Biosciences is delighted to announce that it has made the #21toWatch Companies longlist. The highly respected annual #21toWatch campaign and awards programme showcases the people, companies and ‘things’ that are setting the standards of innovation and...

Stroma Biosciences Announces Appointment of New Chairman

Stroma Biosciences, Ltd, a Cambridge based oncology company today announced the appointment of Dr John Beadle as Executive Chairman. Dr Beadle, who previously held the role of CEO at PsiOxus Therapeutics, joins the Stroma Board at a critical time for growth of the...

Stroma accepted as a Milner Therapeutics Institute Frameshift company

We have been accepted as a Milner Therapeutics Institute Frameshift company providing us with access to state-of-the art of office and lab space in the Cambridge Biomedical Campus (more information found: https://www.milner.cam.ac.uk/ and...